JP2004500326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500326A5 JP2004500326A5 JP2000620913A JP2000620913A JP2004500326A5 JP 2004500326 A5 JP2004500326 A5 JP 2004500326A5 JP 2000620913 A JP2000620913 A JP 2000620913A JP 2000620913 A JP2000620913 A JP 2000620913A JP 2004500326 A5 JP2004500326 A5 JP 2004500326A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- oxo
- naphthyridin
- nonanoic acid
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 80
- 150000001875 compounds Chemical class 0.000 claims 52
- -1 hydroxy, hydroxy Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 34
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 claims 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 11
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- 125000004442 acylamino group Chemical group 0.000 claims 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 230000003042 antagnostic effect Effects 0.000 claims 6
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 4
- 208000006386 Bone Resorption Diseases 0.000 claims 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 230000024279 bone resorption Effects 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- YRKLRKQGAWLYDP-IBGZPJMESA-N (2s)-2-(2-methoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 YRKLRKQGAWLYDP-IBGZPJMESA-N 0.000 claims 3
- KYIUESBVXDONBH-FQEVSTJZSA-N (2s)-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 KYIUESBVXDONBH-FQEVSTJZSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- AYDDTLCITNWPKO-JOCHJYFZSA-N (2R)-2-(2,3-dihydro-1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1ccc2CCOc2c1 AYDDTLCITNWPKO-JOCHJYFZSA-N 0.000 claims 2
- HGMOQTQPWKYBJF-HXUWFJFHSA-N (2R)-2-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc2OCCOc2c1 HGMOQTQPWKYBJF-HXUWFJFHSA-N 0.000 claims 2
- DGUILINMWZCQNV-OAQYLSRUSA-N (2R)-2-(2-cyclopropylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc(nc1)C1CC1 DGUILINMWZCQNV-OAQYLSRUSA-N 0.000 claims 2
- WFGOHYOLAUUXQA-HXUWFJFHSA-N (2R)-2-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound Cc1ncc(cn1)[C@@H](CCC(=O)CCCCc1nc2NCCCc2cc1C)C(O)=O WFGOHYOLAUUXQA-HXUWFJFHSA-N 0.000 claims 2
- GORJZZGBALVRQI-OAQYLSRUSA-N (2R)-2-(6-ethoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CCOc1ccc(cn1)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O GORJZZGBALVRQI-OAQYLSRUSA-N 0.000 claims 2
- CAVMYLVDMTYJKW-GFOWMXPYSA-N (2R)-5-hydroxy-2-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC1=NC=C(C=N1)[C@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CAVMYLVDMTYJKW-GFOWMXPYSA-N 0.000 claims 2
- CITGFEDLBWRGEJ-OZAIVSQSSA-N (2R)-5-hydroxy-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=CC(=CC2=CC=CC=C12)[C@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CITGFEDLBWRGEJ-OZAIVSQSSA-N 0.000 claims 2
- QVQCBDGBIZVTMM-OAQYLSRUSA-N (2R)-5-oxo-2-(2-propan-2-ylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC(C)c1ncc(cn1)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O QVQCBDGBIZVTMM-OAQYLSRUSA-N 0.000 claims 2
- LZQMLZXBYVIKNA-LJQANCHMSA-N (2R)-5-oxo-2-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cncnc1 LZQMLZXBYVIKNA-LJQANCHMSA-N 0.000 claims 2
- HNGVWTANWOACNX-OAQYLSRUSA-N (2R)-7,7-dimethyl-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1ncc(cn1)[C@@H](CCC(=O)CC(C)(C)CCc1ccc2CCCNc2n1)C(O)=O HNGVWTANWOACNX-OAQYLSRUSA-N 0.000 claims 2
- OEJMPXAXGWKGQE-QFIPXVFZSA-N (2S)-2-(1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1ccc2ccoc2c1 OEJMPXAXGWKGQE-QFIPXVFZSA-N 0.000 claims 2
- HGMOQTQPWKYBJF-FQEVSTJZSA-N (2S)-2-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc2OCCOc2c1 HGMOQTQPWKYBJF-FQEVSTJZSA-N 0.000 claims 2
- DGUILINMWZCQNV-NRFANRHFSA-N (2S)-2-(2-cyclopropylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc(nc1)C1CC1 DGUILINMWZCQNV-NRFANRHFSA-N 0.000 claims 2
- CBEYPRXKRIRFIJ-FQEVSTJZSA-N (2S)-2-(2-methylpyrimidin-5-yl)-7-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1ncc(cn1)[C@H](CCCCC(=O)CCc1ccc2CCCNc2n1)C(O)=O CBEYPRXKRIRFIJ-FQEVSTJZSA-N 0.000 claims 2
- FDHJJPVHTYVRIJ-NRFANRHFSA-N (2S)-2-(5-methoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COc1cncc(c1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O FDHJJPVHTYVRIJ-NRFANRHFSA-N 0.000 claims 2
- LUCRVWWAYGIHAB-IBGZPJMESA-N (2S)-2-(5-methylpyrazin-2-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1cnc(cn1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O LUCRVWWAYGIHAB-IBGZPJMESA-N 0.000 claims 2
- GORJZZGBALVRQI-NRFANRHFSA-N (2S)-2-(6-ethoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CCOc1ccc(cn1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O GORJZZGBALVRQI-NRFANRHFSA-N 0.000 claims 2
- CAVMYLVDMTYJKW-ANYOKISRSA-N (2S)-5-hydroxy-2-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC1=NC=C(C=N1)[C@@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CAVMYLVDMTYJKW-ANYOKISRSA-N 0.000 claims 2
- CITGFEDLBWRGEJ-WCSIJFPASA-N (2S)-5-hydroxy-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=CC(=CC2=CC=CC=C12)[C@@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CITGFEDLBWRGEJ-WCSIJFPASA-N 0.000 claims 2
- QVQCBDGBIZVTMM-NRFANRHFSA-N (2S)-5-oxo-2-(2-propan-2-ylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC(C)c1ncc(cn1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O QVQCBDGBIZVTMM-NRFANRHFSA-N 0.000 claims 2
- LZQMLZXBYVIKNA-IBGZPJMESA-N (2S)-5-oxo-2-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cncnc1 LZQMLZXBYVIKNA-IBGZPJMESA-N 0.000 claims 2
- HNGVWTANWOACNX-NRFANRHFSA-N (2S)-7,7-dimethyl-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1ncc(cn1)[C@H](CCC(=O)CC(C)(C)CCc1ccc2CCCNc2n1)C(O)=O HNGVWTANWOACNX-NRFANRHFSA-N 0.000 claims 2
- OEJMPXAXGWKGQE-JOCHJYFZSA-N (2r)-2-(1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2C=COC2=CC([C@@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=C1 OEJMPXAXGWKGQE-JOCHJYFZSA-N 0.000 claims 2
- VNNKGLKYUJUPHO-HXUWFJFHSA-N (2r)-2-(2-ethoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 VNNKGLKYUJUPHO-HXUWFJFHSA-N 0.000 claims 2
- YRKLRKQGAWLYDP-LJQANCHMSA-N (2r)-2-(2-methoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 YRKLRKQGAWLYDP-LJQANCHMSA-N 0.000 claims 2
- MWPVEEPFXLFXMA-LJQANCHMSA-N (2r)-2-(2-methoxypyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 MWPVEEPFXLFXMA-LJQANCHMSA-N 0.000 claims 2
- KYIUESBVXDONBH-HXUWFJFHSA-N (2r)-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 KYIUESBVXDONBH-HXUWFJFHSA-N 0.000 claims 2
- CBEYPRXKRIRFIJ-HXUWFJFHSA-N (2r)-2-(2-methylpyrimidin-5-yl)-7-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCCCC(=O)CCC1=CC=C(CCCN2)C2=N1 CBEYPRXKRIRFIJ-HXUWFJFHSA-N 0.000 claims 2
- CKSPSTLZBJXIKM-MZVUKIKXSA-N (2r)-2-(2-methylpyrimidin-5-yl)-9-(6-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1([C@H](C(O)=O)CCC(=O)CCCCC=2N=C3NCC(CC3=CC=2)C)=CN=C(C)N=C1 CKSPSTLZBJXIKM-MZVUKIKXSA-N 0.000 claims 2
- RGRLZRNIQDXERL-OAQYLSRUSA-N (2r)-2-(2-tert-butylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)(C)C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 RGRLZRNIQDXERL-OAQYLSRUSA-N 0.000 claims 2
- FDHJJPVHTYVRIJ-OAQYLSRUSA-N (2r)-2-(5-methoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COC1=CN=CC([C@@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(O)=O)=C1 FDHJJPVHTYVRIJ-OAQYLSRUSA-N 0.000 claims 2
- LUCRVWWAYGIHAB-LJQANCHMSA-N (2r)-2-(5-methylpyrazin-2-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=CN=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 LUCRVWWAYGIHAB-LJQANCHMSA-N 0.000 claims 2
- IGYRCQAUOKNOCX-GOSISDBHSA-N (2r)-2-(6-methoxypyridazin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=NC(OC)=CC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 IGYRCQAUOKNOCX-GOSISDBHSA-N 0.000 claims 2
- XAYSGSCETLFAQC-HXUWFJFHSA-N (2r)-2-(6-methoxypyridin-3-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 XAYSGSCETLFAQC-HXUWFJFHSA-N 0.000 claims 2
- ACNBIPIEGANMHS-HXUWFJFHSA-N (2r)-2-[2-(dimethylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(N(C)C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 ACNBIPIEGANMHS-HXUWFJFHSA-N 0.000 claims 2
- QHDQGGPLXWADGC-LJQANCHMSA-N (2r)-2-[2-(methylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(NC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 QHDQGGPLXWADGC-LJQANCHMSA-N 0.000 claims 2
- UPNUQZLHTJMHSH-GOSISDBHSA-N (2r)-5-oxo-2-pyrazin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1([C@@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=CN=CC=N1 UPNUQZLHTJMHSH-GOSISDBHSA-N 0.000 claims 2
- KCXMGCPGJGKFNN-HSZRJFAPSA-N (2r)-5-oxo-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC([C@@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 KCXMGCPGJGKFNN-HSZRJFAPSA-N 0.000 claims 2
- PXKRBNCCUNMPMJ-HXUWFJFHSA-N (2r)-5-oxo-2-quinoxalin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=NC([C@@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 PXKRBNCCUNMPMJ-HXUWFJFHSA-N 0.000 claims 2
- IRXDEOIVUJASDE-GOSISDBHSA-N (2r)-9-(3-bromo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Br)=NC2=C1CCCN2 IRXDEOIVUJASDE-GOSISDBHSA-N 0.000 claims 2
- LNBYIIKGGCJLKI-OAQYLSRUSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-ethoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 LNBYIIKGGCJLKI-OAQYLSRUSA-N 0.000 claims 2
- WBNWAXSZYLDMNX-HXUWFJFHSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 WBNWAXSZYLDMNX-HXUWFJFHSA-N 0.000 claims 2
- FGXZHWSARJMWBB-OAQYLSRUSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 FGXZHWSARJMWBB-OAQYLSRUSA-N 0.000 claims 2
- MCVGEJRYKPRVRX-OAQYLSRUSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(6-methoxypyridin-3-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 MCVGEJRYKPRVRX-OAQYLSRUSA-N 0.000 claims 2
- ROBTWMCHZFQAOU-OAQYLSRUSA-N (2r)-9-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C=C)=NC2=C1CCCN2 ROBTWMCHZFQAOU-OAQYLSRUSA-N 0.000 claims 2
- DMHGRCAGNKKTJL-HSZRJFAPSA-N (2r)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxo-2-quinolin-3-ylnonanoic acid Chemical compound C1=CC=CC2=CC([C@H](C(O)=O)CCC(=O)CCCCC3=NC=4NCCCC=4C=C3C)=CN=C21 DMHGRCAGNKKTJL-HSZRJFAPSA-N 0.000 claims 2
- AYDDTLCITNWPKO-QFIPXVFZSA-N (2s)-2-(2,3-dihydro-1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2CCOC2=CC([C@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=C1 AYDDTLCITNWPKO-QFIPXVFZSA-N 0.000 claims 2
- VNNKGLKYUJUPHO-FQEVSTJZSA-N (2s)-2-(2-ethoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 VNNKGLKYUJUPHO-FQEVSTJZSA-N 0.000 claims 2
- MWPVEEPFXLFXMA-IBGZPJMESA-N (2s)-2-(2-methoxypyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 MWPVEEPFXLFXMA-IBGZPJMESA-N 0.000 claims 2
- WFGOHYOLAUUXQA-FQEVSTJZSA-N (2s)-2-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 WFGOHYOLAUUXQA-FQEVSTJZSA-N 0.000 claims 2
- CKSPSTLZBJXIKM-FXMQYSIJSA-N (2s)-2-(2-methylpyrimidin-5-yl)-9-(6-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1([C@@H](C(O)=O)CCC(=O)CCCCC=2N=C3NCC(CC3=CC=2)C)=CN=C(C)N=C1 CKSPSTLZBJXIKM-FXMQYSIJSA-N 0.000 claims 2
- RGRLZRNIQDXERL-NRFANRHFSA-N (2s)-2-(2-tert-butylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)(C)C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 RGRLZRNIQDXERL-NRFANRHFSA-N 0.000 claims 2
- IGYRCQAUOKNOCX-SFHVURJKSA-N (2s)-2-(6-methoxypyridazin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=NC(OC)=CC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 IGYRCQAUOKNOCX-SFHVURJKSA-N 0.000 claims 2
- XAYSGSCETLFAQC-FQEVSTJZSA-N (2s)-2-(6-methoxypyridin-3-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 XAYSGSCETLFAQC-FQEVSTJZSA-N 0.000 claims 2
- ACNBIPIEGANMHS-FQEVSTJZSA-N (2s)-2-[2-(dimethylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(N(C)C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 ACNBIPIEGANMHS-FQEVSTJZSA-N 0.000 claims 2
- QHDQGGPLXWADGC-IBGZPJMESA-N (2s)-2-[2-(methylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(NC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 QHDQGGPLXWADGC-IBGZPJMESA-N 0.000 claims 2
- UPNUQZLHTJMHSH-SFHVURJKSA-N (2s)-5-oxo-2-pyrazin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1([C@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=CN=CC=N1 UPNUQZLHTJMHSH-SFHVURJKSA-N 0.000 claims 2
- KCXMGCPGJGKFNN-QHCPKHFHSA-N (2s)-5-oxo-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC([C@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 KCXMGCPGJGKFNN-QHCPKHFHSA-N 0.000 claims 2
- PXKRBNCCUNMPMJ-FQEVSTJZSA-N (2s)-5-oxo-2-quinoxalin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=NC([C@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 PXKRBNCCUNMPMJ-FQEVSTJZSA-N 0.000 claims 2
- IRXDEOIVUJASDE-SFHVURJKSA-N (2s)-9-(3-bromo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Br)=NC2=C1CCCN2 IRXDEOIVUJASDE-SFHVURJKSA-N 0.000 claims 2
- OHUPCXOWIXFSDO-SFHVURJKSA-N (2s)-9-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Cl)=NC2=C1CCCN2 OHUPCXOWIXFSDO-SFHVURJKSA-N 0.000 claims 2
- LNBYIIKGGCJLKI-NRFANRHFSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-ethoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 LNBYIIKGGCJLKI-NRFANRHFSA-N 0.000 claims 2
- WBNWAXSZYLDMNX-FQEVSTJZSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 WBNWAXSZYLDMNX-FQEVSTJZSA-N 0.000 claims 2
- FGXZHWSARJMWBB-NRFANRHFSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 FGXZHWSARJMWBB-NRFANRHFSA-N 0.000 claims 2
- MCVGEJRYKPRVRX-NRFANRHFSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(6-methoxypyridin-3-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 MCVGEJRYKPRVRX-NRFANRHFSA-N 0.000 claims 2
- DMHGRCAGNKKTJL-QHCPKHFHSA-N (2s)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxo-2-quinolin-3-ylnonanoic acid Chemical compound C1=CC=CC2=CC([C@@H](C(O)=O)CCC(=O)CCCCC3=NC=4NCCCC=4C=C3C)=CN=C21 DMHGRCAGNKKTJL-QHCPKHFHSA-N 0.000 claims 2
- OVPGZOBAJSOERO-CQSZACIVSA-N (3r)-9-[6-(methylamino)pyridin-2-yl]-5-oxo-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCC(=O)C[C@H](CC(O)=O)C=2C=NC=NC=2)=N1 OVPGZOBAJSOERO-CQSZACIVSA-N 0.000 claims 2
- OVPGZOBAJSOERO-AWEZNQCLSA-N (3s)-9-[6-(methylamino)pyridin-2-yl]-5-oxo-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCC(=O)C[C@@H](CC(O)=O)C=2C=NC=NC=2)=N1 OVPGZOBAJSOERO-AWEZNQCLSA-N 0.000 claims 2
- 229940121819 ATPase inhibitor Drugs 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 102000004171 Cathepsin K Human genes 0.000 claims 2
- 108090000625 Cathepsin K Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- 210000002997 osteoclast Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- OHUPCXOWIXFSDO-GOSISDBHSA-N (2r)-9-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Cl)=NC2=C1CCCN2 OHUPCXOWIXFSDO-GOSISDBHSA-N 0.000 claims 1
- ROBTWMCHZFQAOU-NRFANRHFSA-N (2s)-9-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C=C)=NC2=C1CCCN2 ROBTWMCHZFQAOU-NRFANRHFSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims 1
- XKEVCUANHFBLPG-UHFFFAOYSA-N 1-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-7-(2-methylpyrimidin-5-yl)nonan-5-one Chemical compound C=1N=C(C)N=CC=1C(CC)CC(=O)CCCCC1=NC=2NCCCC=2C=C1C1CC1 XKEVCUANHFBLPG-UHFFFAOYSA-N 0.000 claims 1
- RFARBJJIUKDADJ-UHFFFAOYSA-N 2-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CCCCCCCC(C1=C(C=C2CCCNC2=N1)Cl)C(=O)O RFARBJJIUKDADJ-UHFFFAOYSA-N 0.000 claims 1
- JBLQKEHWQSGLSN-UHFFFAOYSA-N 2-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1(CC1)C=1C(=NC=2NCCCC=2C=1)C(C(=O)O)CCCCCCC JBLQKEHWQSGLSN-UHFFFAOYSA-N 0.000 claims 1
- ZDAZYNCFIRTHMI-UHFFFAOYSA-N 2-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C(=C)C=1C(=NC=2NCCCC=2C=1)C(C(=O)O)CCCCCCC ZDAZYNCFIRTHMI-UHFFFAOYSA-N 0.000 claims 1
- QAHKIQBWURDABN-UHFFFAOYSA-N 3-(1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2C=COC2=CC(C(CC(=O)CCCCC=2N=C3NCCCC3=CC=2)CC(=O)O)=C1 QAHKIQBWURDABN-UHFFFAOYSA-N 0.000 claims 1
- LHXUSLZFFIODBJ-UHFFFAOYSA-N 3-(2,3-dihydro-1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2CCOC2=CC(C(CC(=O)CCCCC=2N=C3NCCCC3=CC=2)CC(=O)O)=C1 LHXUSLZFFIODBJ-UHFFFAOYSA-N 0.000 claims 1
- GBWHLRNQBCQMDU-UHFFFAOYSA-N 3-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound O1CCOC2=CC(C(CC(=O)CCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 GBWHLRNQBCQMDU-UHFFFAOYSA-N 0.000 claims 1
- SCYLAETWALMUDS-UHFFFAOYSA-N 3-(2-cyclopropylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCNC2=NC=1CCCCC(=O)CC(CC(=O)O)C(C=N1)=CN=C1C1CC1 SCYLAETWALMUDS-UHFFFAOYSA-N 0.000 claims 1
- ISWGDMYFBALUTB-UHFFFAOYSA-N 3-(2-ethoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 ISWGDMYFBALUTB-UHFFFAOYSA-N 0.000 claims 1
- CKQPZIKYRFZYFW-UHFFFAOYSA-N 3-(2-methoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 CKQPZIKYRFZYFW-UHFFFAOYSA-N 0.000 claims 1
- CQKYNXYYADIHTP-UHFFFAOYSA-N 3-(2-methoxypyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 CQKYNXYYADIHTP-UHFFFAOYSA-N 0.000 claims 1
- MMIMNHFTOYWLHW-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 MMIMNHFTOYWLHW-UHFFFAOYSA-N 0.000 claims 1
- AXWCRKTXRMIKPF-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-7-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CCCC(=O)CCC1=CC=C(CCCN2)C2=N1 AXWCRKTXRMIKPF-UHFFFAOYSA-N 0.000 claims 1
- HDRFULTXFCRTQX-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 HDRFULTXFCRTQX-UHFFFAOYSA-N 0.000 claims 1
- RWGYKDBFESDGHI-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-9-(6-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C=1C=C2CC(C)CNC2=NC=1CCCCC(=O)CC(CC(O)=O)C1=CN=C(C)N=C1 RWGYKDBFESDGHI-UHFFFAOYSA-N 0.000 claims 1
- GWHHCGJNCXNOFE-UHFFFAOYSA-N 3-(2-tert-butylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)(C)C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 GWHHCGJNCXNOFE-UHFFFAOYSA-N 0.000 claims 1
- ZNBIHZSQJAURRN-UHFFFAOYSA-N 3-(5-methoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COC1=CN=CC(C(CC(O)=O)CC(=O)CCCCC=2N=C3NCCCC3=CC=2)=C1 ZNBIHZSQJAURRN-UHFFFAOYSA-N 0.000 claims 1
- DEUWUJFNKOTTIC-UHFFFAOYSA-N 3-(5-methylpyrazin-2-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=CN=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 DEUWUJFNKOTTIC-UHFFFAOYSA-N 0.000 claims 1
- DAUPDEKPSWOESJ-UHFFFAOYSA-N 3-(6-ethoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=CC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 DAUPDEKPSWOESJ-UHFFFAOYSA-N 0.000 claims 1
- FIJQSMQSNSSYTC-UHFFFAOYSA-N 3-(6-methoxypyridazin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=NC(OC)=CC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 FIJQSMQSNSSYTC-UHFFFAOYSA-N 0.000 claims 1
- LFOAWSUGJKSHHB-UHFFFAOYSA-N 3-(6-methoxypyridin-3-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 LFOAWSUGJKSHHB-UHFFFAOYSA-N 0.000 claims 1
- JQZZSYZKNLEXOV-UHFFFAOYSA-N 3-[2-(dimethylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(N(C)C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 JQZZSYZKNLEXOV-UHFFFAOYSA-N 0.000 claims 1
- RCTLBKVHKHPTJY-UHFFFAOYSA-N 3-[2-(methylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(NC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 RCTLBKVHKHPTJY-UHFFFAOYSA-N 0.000 claims 1
- ZGXKNWNJVOZHCG-UHFFFAOYSA-N 5-hydroxy-3-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(O)CCCCC1=CC=C(CCCN2)C2=N1 ZGXKNWNJVOZHCG-UHFFFAOYSA-N 0.000 claims 1
- ZYXRXQZAQSMRHD-UHFFFAOYSA-N 5-hydroxy-3-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)CC(CCCCC=3N=C4NCCCC4=CC=3)O)=CN=C21 ZYXRXQZAQSMRHD-UHFFFAOYSA-N 0.000 claims 1
- SEELZNMZMVOEBU-UHFFFAOYSA-N 5-oxo-3-(2-propan-2-ylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 SEELZNMZMVOEBU-UHFFFAOYSA-N 0.000 claims 1
- CBMAMSBWMAVLPB-UHFFFAOYSA-N 5-oxo-3-pyrazin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCNC2=NC=1CCCCC(=O)CC(CC(=O)O)C1=CN=CC=N1 CBMAMSBWMAVLPB-UHFFFAOYSA-N 0.000 claims 1
- GKNVSRZWLDHKCU-UHFFFAOYSA-N 5-oxo-3-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCNC2=NC=1CCCCC(=O)CC(CC(=O)O)C1=CN=CN=C1 GKNVSRZWLDHKCU-UHFFFAOYSA-N 0.000 claims 1
- QTYNHONNXNWXBB-UHFFFAOYSA-N 5-oxo-3-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC(C(CC(=O)CCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 QTYNHONNXNWXBB-UHFFFAOYSA-N 0.000 claims 1
- OGEHVFFGMRSQAU-UHFFFAOYSA-N 5-oxo-3-quinoxalin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=NC(C(CC(=O)CCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 OGEHVFFGMRSQAU-UHFFFAOYSA-N 0.000 claims 1
- KLHVJOCHLMWJPW-UHFFFAOYSA-N 9-(2,6-diaminopyrimidin-4-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC(N)=NC(N)=N1 KLHVJOCHLMWJPW-UHFFFAOYSA-N 0.000 claims 1
- OXBOFCJANGRIBP-UHFFFAOYSA-N 9-(3-bromo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)Br)=NC2=C1CCCN2 OXBOFCJANGRIBP-UHFFFAOYSA-N 0.000 claims 1
- UWTNKCIZAXFDTL-UHFFFAOYSA-N 9-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)Cl)=NC2=C1CCCN2 UWTNKCIZAXFDTL-UHFFFAOYSA-N 0.000 claims 1
- CLXOWWAVRFIKSW-UHFFFAOYSA-N 9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-ethoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OCC)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 CLXOWWAVRFIKSW-UHFFFAOYSA-N 0.000 claims 1
- QBLMYYIXXTVYAY-UHFFFAOYSA-N 9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(6-methoxypyridin-3-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 QBLMYYIXXTVYAY-UHFFFAOYSA-N 0.000 claims 1
- SMDKAGFIIKXBTI-UHFFFAOYSA-N 9-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C=C)=NC2=C1CCCN2 SMDKAGFIIKXBTI-UHFFFAOYSA-N 0.000 claims 1
- IIDYUNBWJDCHRZ-UHFFFAOYSA-N 9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxo-3-quinolin-3-ylnonanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)CC(=O)CCCCC3=NC=4NCCCC=4C=C3C)=CN=C21 IIDYUNBWJDCHRZ-UHFFFAOYSA-N 0.000 claims 1
- LLSWOFDIDNHBKI-UHFFFAOYSA-N 9-(6-amino-3,5-dimethylpyridin-2-yl)-3-(2-methoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=NC(N)=C(C)C=C1C LLSWOFDIDNHBKI-UHFFFAOYSA-N 0.000 claims 1
- OVPGZOBAJSOERO-UHFFFAOYSA-N 9-[6-(methylamino)pyridin-2-yl]-5-oxo-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCC(=O)CC(CC(O)=O)C=2C=NC=NC=2)=N1 OVPGZOBAJSOERO-UHFFFAOYSA-N 0.000 claims 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 claims 1
- AZNYSXFOKOWWGP-UHFFFAOYSA-N CC1=NC=C(C=N1)C(CC)CC(CC(CCC1=NC=2NCCCC2C=C1)(C)C)=O Chemical compound CC1=NC=C(C=N1)C(CC)CC(CC(CCC1=NC=2NCCCC2C=C1)(C)C)=O AZNYSXFOKOWWGP-UHFFFAOYSA-N 0.000 claims 1
- KZORGNLTMVMRPR-UHFFFAOYSA-N COC1=NC=C(C=N1)C(CC)CC(CCCCC1=NC=2NCCCC2C=C1C1CC1)=O Chemical compound COC1=NC=C(C=N1)C(CC)CC(CCCCC1=NC=2NCCCC2C=C1C1CC1)=O KZORGNLTMVMRPR-UHFFFAOYSA-N 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229940122091 Geranylgeranyltransferase inhibitor Drugs 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 claims 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 101100445392 Xenopus laevis ephb3 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 1
- 230000013823 prenylation Effects 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13710199P | 1999-06-02 | 1999-06-02 | |
| US17921600P | 2000-01-31 | 2000-01-31 | |
| PCT/US2000/014901 WO2000072801A2 (en) | 1999-06-02 | 2000-05-30 | Alpha v integrin receptor antagonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006091925A Division JP2006206604A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
| JP2006091926A Division JP2006232844A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500326A JP2004500326A (ja) | 2004-01-08 |
| JP2004500326A5 true JP2004500326A5 (enExample) | 2004-12-24 |
| JP3808707B2 JP3808707B2 (ja) | 2006-08-16 |
Family
ID=26834930
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620913A Expired - Fee Related JP3808707B2 (ja) | 1999-06-02 | 2000-05-30 | αｖインテグリン受容体拮抗薬 |
| JP2006091926A Withdrawn JP2006232844A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
| JP2006091925A Withdrawn JP2006206604A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006091926A Withdrawn JP2006232844A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
| JP2006091925A Withdrawn JP2006206604A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6410526B1 (enExample) |
| EP (1) | EP1187592B1 (enExample) |
| JP (3) | JP3808707B2 (enExample) |
| KR (1) | KR20020021380A (enExample) |
| CN (1) | CN1589145A (enExample) |
| AT (1) | ATE368462T1 (enExample) |
| AU (1) | AU749351B2 (enExample) |
| BG (1) | BG106232A (enExample) |
| BR (1) | BR0011108A (enExample) |
| CA (1) | CA2373937A1 (enExample) |
| CY (1) | CY1107746T1 (enExample) |
| CZ (1) | CZ20014308A3 (enExample) |
| DE (1) | DE60035779T2 (enExample) |
| DK (1) | DK1187592T3 (enExample) |
| DZ (1) | DZ3263A1 (enExample) |
| EA (1) | EA200101272A1 (enExample) |
| EE (1) | EE200100642A (enExample) |
| ES (1) | ES2288861T3 (enExample) |
| HR (1) | HRP20010895A2 (enExample) |
| HU (1) | HUP0302468A2 (enExample) |
| IL (1) | IL146378A0 (enExample) |
| IS (1) | IS6157A (enExample) |
| NO (1) | NO323906B1 (enExample) |
| PL (1) | PL353364A1 (enExample) |
| PT (1) | PT1187592E (enExample) |
| SK (1) | SK17442001A3 (enExample) |
| TR (1) | TR200103431T2 (enExample) |
| WO (1) | WO2000072801A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2397665A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| DE60126496T2 (de) * | 2000-07-26 | 2007-11-15 | Merck & Co., Inc. | Alpha v integrin-rezeptor-antagonisten |
| AU2001290772A1 (en) * | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002028395A1 (en) * | 2000-10-04 | 2002-04-11 | Merck & Co., Inc. | Phosphoric acid salt of an integrin receptor antagonist |
| CA2432504A1 (en) * | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| AU2002316855B2 (en) | 2001-04-24 | 2008-03-13 | Merck Patent Gmbh | Combination therapy using anti-angiogenic agents and TNFalpha |
| CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| CA2478239A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| US7115596B2 (en) | 2002-12-20 | 2006-10-03 | Pharmacia Corporation | Thiazole compounds as integrin receptor antagonists derivatives |
| WO2004078109A2 (en) * | 2003-03-07 | 2004-09-16 | Merck Sharp & Dohme Limited | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| KR20080089489A (ko) | 2006-01-18 | 2008-10-06 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 |
| CL2008000467A1 (es) * | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| US20100069302A1 (en) | 2007-07-18 | 2010-03-18 | Stefan Krueger | Specific therapy and medicament using integrin ligands for treating cancer |
| EP2217238B1 (en) | 2007-11-08 | 2014-03-12 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| SG176103A1 (en) | 2009-05-25 | 2011-12-29 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| PT2953948T (pt) | 2013-02-07 | 2017-12-12 | Scifluor Life Sciences Inc | Antagonistas de integrina fluorada |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| FI3929196T3 (fi) | 2013-09-24 | 2023-10-02 | Fujifilm Corp | Typpeä sisältävän yhdisteen tai sen suolan tai niiden metallikompleksin farmaseuttinen koostumus |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CA2976634C (en) * | 2015-02-19 | 2023-10-17 | Scifluor Life Sciences, Inc | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| AU2017292754B2 (en) * | 2016-07-05 | 2021-06-17 | Icahn School Of Medicine At Mount Sinai | Tetrahydronaphthyridinepentanamide integrin antagonists |
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| BR112019009245A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| BR112019009129A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| CN116283977A (zh) | 2017-02-28 | 2023-06-23 | 莫菲克医疗股份有限公司 | αvβ6整合蛋白的抑制剂 |
| SG11202101913PA (en) | 2018-08-29 | 2021-03-30 | Morphic Therapeutic Inc | INHIBITING aV ß6 INTEGRIN |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843798A (en) | 1973-03-12 | 1974-10-22 | Stanley Drug Products Inc | Methods and compositions for inducing resistance to bacterial infections |
| US5025025A (en) | 1989-06-28 | 1991-06-18 | Ciba-Geigy Corporation | (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity |
| WO1992019595A1 (en) | 1991-05-07 | 1992-11-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| CA2117282A1 (en) | 1991-11-22 | 1993-05-27 | Ofer Lider | Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprosing them |
| US5786373A (en) | 1992-10-14 | 1998-07-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| ES2186720T3 (es) | 1994-05-27 | 2003-05-16 | Merck & Co Inc | Composiciones para inhibir la reabsorcion osea mediada por osteoclastos. |
| AU713676B2 (en) | 1996-01-16 | 1999-12-09 | Merck & Co., Inc. | Integrin receptor antagonists |
| DK0796855T3 (da) | 1996-03-20 | 2002-05-27 | Hoechst Ag | Hæmmere af knogleresorption og vitronectin-receptorantagonister |
| WO1997037655A1 (en) | 1996-04-10 | 1997-10-16 | Merck & Co., Inc. | αvβ3 ANTAGONISTS |
| US5668159A (en) | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
| CA2263999A1 (en) | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
| DE69720771T2 (de) * | 1996-10-30 | 2004-01-29 | Merck & Co Inc | Integrin antagonist |
| JP2001504456A (ja) | 1996-10-30 | 2001-04-03 | メルク エンド カンパニー インコーポレーテッド | インテグリン拮抗薬 |
| AU729869B2 (en) | 1997-01-17 | 2001-02-15 | Merck & Co., Inc. | Integrin antagonists |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| HUP0100397A3 (en) * | 1997-12-17 | 2002-10-28 | Merck & Co Inc | Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| DE69830806T2 (de) | 1997-12-17 | 2006-04-27 | Merck & Co., Inc. | Integrinrezeptor antagonisten |
| EA003095B1 (ru) | 1997-12-17 | 2002-12-26 | Мерк Энд Ко., Инк. | Антагонисты рецепторов интегринов |
-
2000
- 2000-05-30 AU AU57246/00A patent/AU749351B2/en not_active Ceased
- 2000-05-30 BR BR0011108-2A patent/BR0011108A/pt not_active IP Right Cessation
- 2000-05-30 PT PT00942652T patent/PT1187592E/pt unknown
- 2000-05-30 EA EA200101272A patent/EA200101272A1/ru unknown
- 2000-05-30 PL PL00353364A patent/PL353364A1/xx not_active Application Discontinuation
- 2000-05-30 DZ DZ003263A patent/DZ3263A1/fr active
- 2000-05-30 CN CNA00811157XA patent/CN1589145A/zh active Pending
- 2000-05-30 TR TR2001/03431T patent/TR200103431T2/xx unknown
- 2000-05-30 WO PCT/US2000/014901 patent/WO2000072801A2/en not_active Ceased
- 2000-05-30 HR HR20010895A patent/HRP20010895A2/xx not_active Application Discontinuation
- 2000-05-30 CA CA002373937A patent/CA2373937A1/en not_active Abandoned
- 2000-05-30 KR KR1020017015498A patent/KR20020021380A/ko not_active Ceased
- 2000-05-30 IL IL14637800A patent/IL146378A0/xx unknown
- 2000-05-30 CZ CZ20014308A patent/CZ20014308A3/cs unknown
- 2000-05-30 EP EP00942652A patent/EP1187592B1/en not_active Expired - Lifetime
- 2000-05-30 HU HU0302468A patent/HUP0302468A2/hu unknown
- 2000-05-30 DK DK00942652T patent/DK1187592T3/da active
- 2000-05-30 DE DE60035779T patent/DE60035779T2/de not_active Expired - Fee Related
- 2000-05-30 SK SK1744-2001A patent/SK17442001A3/sk unknown
- 2000-05-30 ES ES00942652T patent/ES2288861T3/es not_active Expired - Lifetime
- 2000-05-30 EE EEP200100642A patent/EE200100642A/xx unknown
- 2000-05-30 JP JP2000620913A patent/JP3808707B2/ja not_active Expired - Fee Related
- 2000-05-30 AT AT00942652T patent/ATE368462T1/de not_active IP Right Cessation
- 2000-05-31 US US09/583,522 patent/US6410526B1/en not_active Expired - Fee Related
-
2001
- 2001-11-13 IS IS6157A patent/IS6157A/is unknown
- 2001-11-30 NO NO20015858A patent/NO323906B1/no not_active IP Right Cessation
- 2001-12-18 BG BG106232A patent/BG106232A/xx unknown
-
2006
- 2006-03-29 JP JP2006091926A patent/JP2006232844A/ja not_active Withdrawn
- 2006-03-29 JP JP2006091925A patent/JP2006206604A/ja not_active Withdrawn
-
2007
- 2007-09-27 CY CY20071101242T patent/CY1107746T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500326A5 (enExample) | ||
| JP2003520271A5 (enExample) | ||
| ES2974985T3 (es) | Inhibidores de FGFR y métodos de uso de los mismos | |
| CA2397194A1 (en) | Alpha v integrin receptor antagonists | |
| JP7654071B2 (ja) | 複素環スピロ化合物及び使用方法 | |
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| AU2012339499B2 (en) | Aminoquinazoline derivatives and their salts and methods of use | |
| TW201822764A (zh) | Syk抑制劑 | |
| JP2020504739A (ja) | Ｐｄ−ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５−ｃ］ピリジン誘導体 | |
| AU2022292554A1 (en) | Urea derivatives which can be used to treat cancer | |
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| CN104513259B (zh) | 取代脲衍生物及其在药物中的应用 | |
| JP2017531039A5 (enExample) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2013537210A5 (enExample) | ||
| HRP20121069T1 (hr) | Supstituirani derivati amida kao inhibitori protein kinaze | |
| KR20150118102A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 | |
| RS52939B (sr) | Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa | |
| JP2002508326A5 (enExample) | ||
| JP2004500326A (ja) | αｖインテグリン受容体拮抗薬 | |
| KR20150083833A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법 | |
| CN111051305A (zh) | 治疗性杂环化合物 | |
| RU97120116A (ru) | Альфа-замещенные пиримидин-тиоалкильные и алкилэфирные соединения | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| AR084067A1 (es) | Composiciones farmaceuticas |